Skip to main content
Erschienen in: Der Nervenarzt 5/2016

09.12.2015 | Parkinson-Krankheit | Übersichten

Evidenz zur Behandlung der Parkinson-assoziierten Psychose

verfasst von: Dr. R. Haussmann, M. Bauer, M. Donix

Erschienen in: Der Nervenarzt | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Psychotische Symptome bei Parkinson-Patienten sind häufige Phänomene. Das Auftreten einer Parkinson-assoziierten Psychose ist häufig mit einer immensen Belastung für Pflegende, der Notwendigkeit einer Heimunterbringung und mit einer erhöhten Mortalität vergesellschaftet. Die Behandlung der Parkinson-assoziierten Psychose erfordert eine differenzierte Risiko-Nutzen-Abwägung, da sowohl die Reduktion potenziell propsychotischer, dopaminerger Medikamente als auch die neuroleptische Behandlung die motorischen Funktionen zu einem erheblichen Maß einschränken können. Wir geben eine Übersicht zu klinischen Aspekten der Parkinson-assoziierten Psychose und ihrer evidenzbasierten Behandlung.
Literatur
1.
Zurück zum Zitat Tarsy D (2015) Management of comorbid problems associated with Parkinson disease. Wolters Kluwer, S 1–8. http://www.uptodate.com. Zugegriffen: 18. März 2015 Tarsy D (2015) Management of comorbid problems associated with Parkinson disease. Wolters Kluwer, S 1–8. http://​www.​uptodate.​com.​ Zugegriffen: 18. März 2015
2.
3.
Zurück zum Zitat Fenelon G, Alves G (2010) Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci 289(1–2):12–17 Fenelon G, Alves G (2010) Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci 289(1–2):12–17
4.
Zurück zum Zitat Wint DP, Okun MS, Fernandez HH (2004) Psychosis in Parkinson’s disease. J Geriatr Psychiatry Neurol 17:127–136CrossRefPubMed Wint DP, Okun MS, Fernandez HH (2004) Psychosis in Parkinson’s disease. J Geriatr Psychiatry Neurol 17:127–136CrossRefPubMed
5.
Zurück zum Zitat Biousse V et al (2004) Ophthalmologic features of Parkinson’s disease. Neurology 62(2):177–180CrossRefPubMed Biousse V et al (2004) Ophthalmologic features of Parkinson’s disease. Neurology 62(2):177–180CrossRefPubMed
6.
Zurück zum Zitat Goetz CG et al (1998) Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 51:811–814CrossRefPubMed Goetz CG et al (1998) Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 51:811–814CrossRefPubMed
7.
Zurück zum Zitat Levy G et al (2002) The association of incident dementia with mortality in PD. Neurology 59(11):1708–1713CrossRefPubMed Levy G et al (2002) The association of incident dementia with mortality in PD. Neurology 59(11):1708–1713CrossRefPubMed
8.
Zurück zum Zitat Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 45(4):669–671CrossRefPubMed Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 45(4):669–671CrossRefPubMed
9.
Zurück zum Zitat Factor SA et al (2003) Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology 60:1756–1761CrossRefPubMed Factor SA et al (2003) Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology 60:1756–1761CrossRefPubMed
11.
Zurück zum Zitat Jessen F, Deuschl G, Maier W (2009) S3-Leitline „Demenzen. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN). Deutsche Gesellschaft für Neurologie (DGN) Jessen F, Deuschl G, Maier W (2009) S3-Leitline „Demenzen. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN). Deutsche Gesellschaft für Neurologie (DGN)
12.
Zurück zum Zitat Eggert KM, Oertel WH, Reichmann H (2012) Leitlinie Parkinson-Syndrome – Diagnostik und Therapie. Deutsche Gesellschaft für Neurologie Eggert KM, Oertel WH, Reichmann H (2012) Leitlinie Parkinson-Syndrome – Diagnostik und Therapie. Deutsche Gesellschaft für Neurologie
13.
Zurück zum Zitat Goldman JG, Vaughan C, Goetz CG (2011) An update expert opinion on management and research strategies in Parkinson’s disease psychosis. Expert Opin Pharmacother 12:2009–2024CrossRefPubMedPubMedCentral Goldman JG, Vaughan C, Goetz CG (2011) An update expert opinion on management and research strategies in Parkinson’s disease psychosis. Expert Opin Pharmacother 12:2009–2024CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Muller AJ et al (2014) Visual hallucinations in Parkinson’s disease: theoretical models. Mov Disord 29:1591–1598CrossRefPubMed Muller AJ et al (2014) Visual hallucinations in Parkinson’s disease: theoretical models. Mov Disord 29:1591–1598CrossRefPubMed
15.
Zurück zum Zitat Fenelon G et al (2000) Hallucinations in Parkinsons’s disease: prevalence, phenomenology and risk factors. Brain 123:733–745CrossRefPubMed Fenelon G et al (2000) Hallucinations in Parkinsons’s disease: prevalence, phenomenology and risk factors. Brain 123:733–745CrossRefPubMed
16.
Zurück zum Zitat Friedman JH (2011) Atypical antipsychotic drugs in the treatment of Parkinson’s disease. J Pharm Pract 24(6):534–540CrossRefPubMed Friedman JH (2011) Atypical antipsychotic drugs in the treatment of Parkinson’s disease. J Pharm Pract 24(6):534–540CrossRefPubMed
17.
Zurück zum Zitat Chou KL et al (2005) Drug-induced Psychosis in Parkinson Disease – Phenomenology and Correlations Among Psychosis Rating Instruments. Clin Neuropharmacol 28:215–219CrossRefPubMed Chou KL et al (2005) Drug-induced Psychosis in Parkinson Disease – Phenomenology and Correlations Among Psychosis Rating Instruments. Clin Neuropharmacol 28:215–219CrossRefPubMed
18.
Zurück zum Zitat Ravina B et al (2007) Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIHM work group. Mov Disord 22:1061–1068CrossRefPubMed Ravina B et al (2007) Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIHM work group. Mov Disord 22:1061–1068CrossRefPubMed
19.
Zurück zum Zitat Miyasaki JM et al (2006) Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66(7):996–1002CrossRefPubMed Miyasaki JM et al (2006) Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66(7):996–1002CrossRefPubMed
20.
Zurück zum Zitat Melamed E (1996) Neurobehavioral abnormalities in Parkinson’s disease. In: Watts RL, Koller WC (Hrsg) Movement disorders. McGraw Hill, New York, S 257–262 Melamed E (1996) Neurobehavioral abnormalities in Parkinson’s disease. In: Watts RL, Koller WC (Hrsg) Movement disorders. McGraw Hill, New York, S 257–262
21.
Zurück zum Zitat Miller R (2009) Machanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: PART 1. Curr Neuropharmacol 7:302–314CrossRefPubMedPubMedCentral Miller R (2009) Machanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: PART 1. Curr Neuropharmacol 7:302–314CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Sawada H et al (2013) Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study. BMC Neurol 13:1–8CrossRef Sawada H et al (2013) Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study. BMC Neurol 13:1–8CrossRef
23.
24.
Zurück zum Zitat Frieling H et al (2007) Treating dopamimetic psychosis in Parkinsons’s disease: structured review and meta-analysis. Eur Neuropsychopharmacol 17:165–171CrossRefPubMed Frieling H et al (2007) Treating dopamimetic psychosis in Parkinsons’s disease: structured review and meta-analysis. Eur Neuropsychopharmacol 17:165–171CrossRefPubMed
25.
Zurück zum Zitat Goldman JG, Holden S (2014) Treatment of psychosis and dementia in Parkinson’s disease. Curr Treat Options Neurol 16:1–25CrossRef Goldman JG, Holden S (2014) Treatment of psychosis and dementia in Parkinson’s disease. Curr Treat Options Neurol 16:1–25CrossRef
26.
Zurück zum Zitat Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson’s disease. Neurology 56:S1–S88CrossRefPubMed Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson’s disease. Neurology 56:S1–S88CrossRefPubMed
27.
Zurück zum Zitat Barnes J, David AS (2001) Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 70:727–733CrossRefPubMedPubMedCentral Barnes J, David AS (2001) Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 70:727–733CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Rabey JM et al (1995) Low-dose clozapine in the treatment of levodopa-inducd mental disturbances in Parkinson’s disease. Neurology 45:432CrossRefPubMed Rabey JM et al (1995) Low-dose clozapine in the treatment of levodopa-inducd mental disturbances in Parkinson’s disease. Neurology 45:432CrossRefPubMed
29.
Zurück zum Zitat Group TPS (1999) Low-dose clozaine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 340:757CrossRef Group TPS (1999) Low-dose clozaine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 340:757CrossRef
30.
31.
Zurück zum Zitat Schulte P (2006) Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Pharmacother 40:683CrossRef Schulte P (2006) Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Pharmacother 40:683CrossRef
32.
Zurück zum Zitat Factor SA et al (2001) Clozapine for the treatment of drug-induced psychosis in Parkinsons’s disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 16:135–139CrossRefPubMed Factor SA et al (2001) Clozapine for the treatment of drug-induced psychosis in Parkinsons’s disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 16:135–139CrossRefPubMed
33.
Zurück zum Zitat Pollak P et al (2004) Clozapine in drug induced psychosis in Parkinsons’s disease: a rondomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75:689–695CrossRefPubMedPubMedCentral Pollak P et al (2004) Clozapine in drug induced psychosis in Parkinsons’s disease: a rondomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75:689–695CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Ondo WG et al (2005) Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopamingeric-induced hallucinations in Parkinson’s disease. Mov Disord 8:958–963CrossRef Ondo WG et al (2005) Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopamingeric-induced hallucinations in Parkinson’s disease. Mov Disord 8:958–963CrossRef
35.
Zurück zum Zitat Kurlan R et al (2007) Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 68:1356–1363CrossRefPubMed Kurlan R et al (2007) Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 68:1356–1363CrossRefPubMed
36.
Zurück zum Zitat Rabey JM et al (2007) Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’duration. Mov Disord 22:313–318CrossRefPubMed Rabey JM et al (2007) Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’duration. Mov Disord 22:313–318CrossRefPubMed
37.
Zurück zum Zitat Breier A et al (2002) Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry 52:438–445CrossRefPubMed Breier A et al (2002) Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry 52:438–445CrossRefPubMed
38.
Zurück zum Zitat Nichols MJ et al (2013) A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease. F1000Res 1–13 Nichols MJ et al (2013) A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease. F1000Res 1–13
39.
Zurück zum Zitat Meltzer HY et al (2010) Pimavanserin, a serotonin 2 a reveptor inverse agoniste, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology 35:881–892CrossRefPubMedPubMedCentral Meltzer HY et al (2010) Pimavanserin, a serotonin 2 a reveptor inverse agoniste, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology 35:881–892CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Cummings J et al (2014) Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383:533–540CrossRefPubMed Cummings J et al (2014) Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383:533–540CrossRefPubMed
41.
Zurück zum Zitat Friedman JH (2012) Melperone is ineffective in treating Parkinson’s disease psychosis. Mov Disord 27:803–804CrossRefPubMed Friedman JH (2012) Melperone is ineffective in treating Parkinson’s disease psychosis. Mov Disord 27:803–804CrossRefPubMed
42.
Zurück zum Zitat Merims D et al (2006) Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol 29:331–337CrossRefPubMed Merims D et al (2006) Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol 29:331–337CrossRefPubMed
43.
Zurück zum Zitat Morgante L et al (2002) Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson’s disease. Neurol Sci 23:89–90CrossRef Morgante L et al (2002) Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson’s disease. Neurol Sci 23:89–90CrossRef
44.
Zurück zum Zitat Morgante L et al (2004) Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 27:153–156CrossRefPubMed Morgante L et al (2004) Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 27:153–156CrossRefPubMed
45.
Zurück zum Zitat Pintor L et al (2012) Ziprasidone versus clozapine in the treatment of psychotic symptoms in parkinson disease: a randomized open clinical trial. Clin Neuropharmacol 35:61–66CrossRefPubMed Pintor L et al (2012) Ziprasidone versus clozapine in the treatment of psychotic symptoms in parkinson disease: a randomized open clinical trial. Clin Neuropharmacol 35:61–66CrossRefPubMed
46.
Zurück zum Zitat Goet CG et al (2000) Olanzapine and Clozapine – Comparative effects on motor function in hallucinating PD patients. Neurology 55:789–794CrossRef Goet CG et al (2000) Olanzapine and Clozapine – Comparative effects on motor function in hallucinating PD patients. Neurology 55:789–794CrossRef
47.
Zurück zum Zitat Ellis T et al (2000) Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 12:364–369CrossRefPubMed Ellis T et al (2000) Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 12:364–369CrossRefPubMed
Metadaten
Titel
Evidenz zur Behandlung der Parkinson-assoziierten Psychose
verfasst von
Dr. R. Haussmann
M. Bauer
M. Donix
Publikationsdatum
09.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Der Nervenarzt / Ausgabe 5/2016
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI
https://doi.org/10.1007/s00115-015-4438-y

Weitere Artikel der Ausgabe 5/2016

Der Nervenarzt 5/2016 Zur Ausgabe

Neu in den Fachgebieten Neurologie und Psychiatrie